Physician profile
Ashish Shah
NPI 1780847384
$10,229.12
in general payments reported to CMS, 2019-2025
38 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $264 · 2021: $749 · 2022: $1,417 · 2023: $1,773 · 2024: $2,444 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,822 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,821.55 |
| Education | $138.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,284.37 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Boston Scientific Corporation | $1,382.08 | 2019-2024 | Spyglass |
| Janssen Biotech, INC. | $1,278.63 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $762.25 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $407.43 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $328.24 | 2024-2025 | Zenpep, Vowst |
| Regeneron Pharmaceuticals, INC. | $319.29 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $316.49 | 2022-2025 | Ibsrela |
| Pfizer INC. | $308.05 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $298.07 | 2022-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.30 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $241.73 | 2023-2025 | |
| Qol Medical, LLC | $219.63 | 2023-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $194.46 | 2019-2024 | Dificid |
| Celltrion USA INC. | $154.12 | 2024-2025 | Vegzelma, Zymfentra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $149.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $145.84 | 2022-2025 | Dupixent |
| Vivus LLC | $138.67 | 2019-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $129.75 | 2021-2023 | |
| Ethicon US, LLC | $122.47 | 2019 | |
| Medtronic, INC. | $119.34 | 2023 | Prodigi |
| Braintree Laboratories, INC. | $107.26 | 2022-2024 | Sutab, Suflave |
| Lilly USA, LLC | $78.44 | 2024 | Omvoh |
| Gilead Sciences, INC. | $75.97 | 2024 | |
| Mauna Kea Technologies, INC. | $49.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.01 | 2023 | Cyltezo |
| Shionogi INC | $42.16 | 2019 | |
| Daiichi Sankyo INC. | $36.41 | 2019-2021 | |
| Alfasigma USA, INC. | $35.18 | 2021 | |
| Melinta Therapeutics, LLC | $33.07 | 2024 | Rezzayo |
| Phathom Pharmaceuticals, INC. | $30.62 | 2024-2025 | Voquezna |
| Biocon Biologics INC | $29.52 | 2025 | Yesintek |
| Organon LLC | $26.89 | 2023 | |
| Dova Pharmaceuticals | $18.28 | 2019 | |
| Redhill Biopharma INC. | $18.15 | 2020 | |
| Intercept Pharmaceuticals, INC. | $14.44 | 2023 | Ocaliva |
| Shire North American Group INC | $13.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.